MiR-9 and miR-21 as prognostic biomarkers for recurrence in papillary thyroid cancer

Sondermann, Adriana; Andreghetto, Flávia Maziero; Moulatlet, Ana Carolina Bernardini; Victor, Elivane da Silva; Castro, Marí­lia Germanos de; Nunes, Fábio Daumas; Brandão, Lenine Garcia; Severino, Patrícia

doi:10.1007/s10585-015-9724-3

Cited by 76 publications

(88 citation statements)

References 81 publications

(104 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In TCGA data, a more aggressive phenotype of thyroid cancer was also correlated with overexpression of miR-21 and miR-146b, as well as the loss of miR-204 (47). Later, the expression levels of miR-21 and miR-9 were also associated with the metastatic potential of tumor cells and proved to be good predictors of nodal metastasis (53).…”

Section: Micrornas In Cancer Prognosticsmentioning

confidence: 99%

MECHANISMS IN ENDOCRINOLOGY: MicroRNA in diagnostics and therapy of thyroid cancer

Wójcicka

Kolanowska

Jażdżewski

2016

European Journal of Endocrinology

View full text Add to dashboard Cite

MicroRNAs, short non-coding regulators of the gene expression, are subjects of numerous investigations assessing their potential use in the diagnostics and management of human diseases. In this review, we focus on studies that analyze the utility of microRNAs as novel diagnostic and therapeutic tools in follicular cell-derived thyroid carcinomas. This very interesting and promising field brings new insight into future strategies for personalized medicine.

show abstract

Section: Micrornas In Cancer Prognosticsmentioning

confidence: 99%

MECHANISMS IN ENDOCRINOLOGY: MicroRNA in diagnostics and therapy of thyroid cancer

Wójcicka

Kolanowska

Jażdżewski

2016

European Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…However, only sporadic studies have so far focused on the association between miR deregulation and thyroid cancer prognosis and therapy [40,55,56,57,58,59]. …”

Section: Prognostic Mirsmentioning

confidence: 99%

“…Therapeutic inhibition of miR-146b in dedifferentiated thyroid carcinoma represents a promising way to enhance radioiodine uptake and the efficacy of radioactive therapy [57]. However, Sondermann et al [59] found no significant differences in miR-146b expression between recurrent and nonrecurrent papillary carcinomas.…”

Section: Prognostic Mirsmentioning

confidence: 99%

Pathobiology of MicroRNAs and Their Emerging Role in Thyroid Fine-Needle Aspiration

2015

View full text Add to dashboard Cite

Objective: MicroRNAs (miRs) are noncoding, single-stranded regulatory RNA molecules involved in the posttranscriptional regulation of gene expression. They control the development and maintenance of the diverse cellular processes including proliferation, differentiation, motility and apoptosis. Expression of miRs is tissue-specific and each alteration of the tissue miR profile is associated with a distinct disease status. Study Design: We reviewed the literature on the expression of miRs in thyroid tumors, focusing on methodology and diagnostic and prognostic output. Separately, we analyzed 11 studies on miR profiles in thyroid cytological material. Results: Numerous studies have evaluated the miR profiles of thyroid tumors in an attempt to find a possible diagnostic and prognostic role. Both downregulation and upregulation of numerous miRs was found, but differences between the surgical pathology specimens and corresponding fine-needle aspirates in the expression of the same miRs were also reported. Conclusions: The results from surgically resected material cannot be extrapolated into preoperative use without validation. For diagnostic use, the strong overlap between follicular adenoma and follicular carcinoma miR profiles is challenging. In summary, miR-221 and miR-222 are consistently upregulated in different types of thyroid carcinomas and might be used as markers of malignancy.

show abstract

“…Thyroid cancer is the most common subtype of endocrine malignancy, with 300,000 new cases per year, and ~40,000 mortalities per year, worldwide (1). The incidence of thyroid cancer has increased in recent decades (2).…”

Section: Introductionmentioning

confidence: 99%

MicroRNA‑335 is downregulated in papillary thyroid cancer and suppresses cancer cell growth, migration and invasion by directly targeting ZEB2

Kan

Yang

2017

Oncol Lett

View full text Add to dashboard Cite

Abstract. MicroRNAs (miRs) are a group of short, endogenous, non-protein-coding and single-stranded RNAs that regulate gene expression by binding to the 3'-untranslated region (3'UTR) of mRNAs, which results in their degradation or translational repression. The aim of the present study was to investigate the expression and function of miR-335 in human papillary thyroid cancer (PTC). Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) was performed to quantify the relative miR-335 expression levels in PTC tissues and cell lines. The effect of miR-335 on the proliferation, migration and invasion of PTC cells was assessed by an MTT assay, and transwell migration and invasion assays, respectively. Dual-luciferase reporter assays were employed to explore whether miR-335 directly targeted the 3'UTR of the potential target gene zinc finger E-box binding homeobox 2 (ZEB2). RT-qPCR and western blotting were adopted to assess the effect of miR-335 on the mRNA and protein expression of ZEB2. RT-qPCR revealed that miR-335 was downregulated in PTC tissues and cell lines. The MTT assay and transwell migration and invasion assays demonstrated that the overexpression of miR-335 significantly inhibited the proliferation, migration and invasion of PTC cells. ZEB2 was identified as a direct target of miR-335 with computational analysis, which was confirmed with a dual-luciferase reporter assay, RT-qPCR and western blotting. The knockdown of ZEB2 significantly inhibited the proliferation, migration and invasion of PTC cells, indicating that ZEB2 may be a functional target of miR-335. Taken together, these findings suggested that miR-335 functioned as a tumor suppressor and suppressed the growth and metastatic behavior of PTC cells by targeting ZEB2. IntroductionThyroid cancer is the most common subtype of endocrine malignancy, with 300,000 new cases per year, and ~40,000 mortalities per year, worldwide (1). The incidence of thyroid cancer has increased in recent decades (2). It can be categorized into four major histologic groups, including papillary thyroid cancer (PTC), follicular thyroid cancer, poorly differentiated carcinoma and anaplastic thyroid cancer (3). PTC accounts for 80-90% of all thyroid cancer cases (4).A number of factors have been demonstrated to be associated with PTC progression, including genetic factors, environmental exposure, epigenetic alteration, nodular disease of the thyroid and radiation exposure (5,6). The prognosis of PTC patients is associated with their age, tumor size, lymph node invasion and distant metastasis (7). Currently, the standard therapeutic treatment for PTC is complete thyroidectomy followed by radioiodine and levothyroxine therapy (8). However, ~10% of patients with PTC develop recurrence and metastasis, which are associated with poor prognosis (9). Thus, it is necessary to characterize the molecular mechanisms of PTC initiation and development, and to develop novel, targeted therapies for PTC.The abnormal expression of microRNAs (miRNAs/miRs) has been implicated in ...

show abstract

MiR-9 and miR-21 as prognostic biomarkers for recurrence in papillary thyroid cancer

Cited by 76 publications

References 81 publications

MECHANISMS IN ENDOCRINOLOGY: MicroRNA in diagnostics and therapy of thyroid cancer

MECHANISMS IN ENDOCRINOLOGY: MicroRNA in diagnostics and therapy of thyroid cancer

Pathobiology of MicroRNAs and Their Emerging Role in Thyroid Fine-Needle Aspiration

MicroRNA‑335 is downregulated in papillary thyroid cancer and suppresses cancer cell growth, migration and invasion by directly targeting ZEB2

Contact Info

Product

Resources

About